Tag: Corbus Pharmaceuticals

July 25, 2018

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) has announced that it will proceed with a Phase 3 trial evaluating the efficacy and safety...
July 20, 2018

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to...
March 12, 2018

Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update

Corbus Pharmaceuticals (NASDAQ: CRBP) a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 31, 2018

Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design

Corbus Pharmaceuticals (NASDAQ: CRBP) a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that...
December 22, 2017

Corbus Pharmaceuticals Kicks Off Phase 2 Study

Corbus Pharmaceuticals Holdings announced the start of their phase 2 clinical study of anabasum, treating systemic lupus erythematosus.
December 14, 2017

Corbus Kicks Off Phase 3 Study RESOLVE-1

Corbus Pharmaceuticals Holdings announced it started their Phase 3 study for the efficacy and safety of anabasum in the treatment...
November 27, 2017

Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Corbus Pharmaceuticals announced it received a patent from the US Patent and Trademark Office covering the use of pharmaceutical compositions...